| Document Date: 2005-06-28 09:23:48
Open Document File Size: 326,43 KBShare Result on Facebook
Company ITT / / Event Product Issues / / IndustryTerm tartrate oral solution / treatment of overactive bladder with symptoms / investigational product / food / / MedicalCondition spinal dysraphism / overactive bladder / cerebral palsy / myelomeningocele / nocturnal enuresis / detrusor hyperreflexia / urinary retention / neurologic disease / stable neurological disease / contraction / traumatic spinal cord injury / clinically significant urinary tract infection / severe constipation / urge urinary incontinence / spinal cord injury / urinary urge incontinence / / MedicalTreatment catheterizations / contraception / drainage / catheterization / / Organization Pediatric Exclusivity Board / / Position Executive / / Product Detrol LA Capsules / IR tablet / Detrol LA / tolterodine / Detrol / patients / children The trial designs / children / /
SocialTag |
NDA[removed] – SE-8 supplement 006 BPCA Clinical Review Drug: Detrol LA Capsules (tolterodine tartrate) 1.0 Brief Background: Detrol LA is currently approved in adults for the treatment of overactive bladder with symptom